KRAS突变与结直肠癌患者静脉血栓栓塞风险:丹麦人群队列研究
结果显示KRAS突变组1年VTE风险为4.6%,野生型组为3.1%,校正后HR为1.37(95%CI 1.12-1.67),提示KRAS突变与VTE风险升高相关。
要点
- KRAS突变型结直肠癌患者1年VTE风险为4.6%,高于野生型的3.1%。
- 校正后KRAS突变与VTE风险升高相关(HR 1.37,95%CI 1.12-1.67)。
- KRAS亚型间异质性明显,未明确标注的密码子13突变风险最高(HR 2.19)。
核心结论
- 在接受KRAS检测的结直肠癌患者中,KRAS突变与静脉血栓栓塞风险升高相关。
研究设计与样本
- KRAS突变组4602例(44%),中位年龄71岁,男性占56%。
主要发现
- 1年随访期间共发生399例VTE事件。
- KRAS突变组1年VTE风险为4.6%(95%CI 4.0-5.2),野生型组为3.1%(95%CI 2.7-3.6)。
- KRAS突变 vs 野生型的校正HR为1.37(95%CI 1.12-1.67);PE的HR为1.44(95%CI 1.13-1.84),DVT的HR为1.22(95%CI 0.85-1.75)。
- KRAS亚型间异质性显著,未明确标注的密码子13突变校正HR为2.19(95%CI 1.38-3.46)。
临床怎么用
- 对于接受KRAS检测的结直肠癌患者,KRAS突变状态可能有助于识别VTE高风险人群。
- KRAS密码子13突变患者VTE风险更高,需加强血栓监测与预防评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Kirsten rat sarcoma viral proto-oncogene (KRAS) mutations may promote a prothrombotic state through tumor-related activation of coagulation pathways. However, evidence for an association with venous thromboembolism (VTE) in colorectal cancer (CRC) patients remains inconclusive. OBJECTIVES: To examine the association between KRAS mutation status and VTE risk. METHODS: We conducted a population-based cohort study using Danish nationwide registries. We included patients diagnosed with stages I to IV CRC who underwent somatic KRAS mutation testing between 2015 and 2023. We computed 1-year risks of VTE, deep vein thrombosis (DVT), and pulmonary embolism (PE) using the Aalen-Johansen method and calculated adjusted hazard ratios (HRs) using cause-specific Cox proportional hazards regression. RESULTS: The study included 10 544 patients with CRC who underwent KRAS testing (4602 [44%] with KRAS mutations; median age 71 years; 56% male). During 1 year of follow-up, 399 VTE events occurred. The 1-year risk of VTE was 4.6% (95% CI, 4.0-5.2) in the KRAS-mutated group and 3.1% (95% CI, 2.7-3.6) in the KRAS-wild-type group. The adjusted HR for VTE comparing KRAS mutations vs wild-type was 1.37 (95% CI, 1.12-1.67), with estimates of 1.44 (95% CI, 1.13-1.84) for PE and 1.22 (95% CI, 0.85-1.75) for DVT. Substantial heterogeneity was observed across KRAS subtypes, with the highest hazards for unspecified codon 13 mutations (adjusted HR, 2.19; 95% CI, 1.38-3.46) compared with those with KRAS wild-type. CONCLUSION: KRAS mutations were associated with an increased risk of VTE in patients with CRC who underwent KRAS testing.
引用
- Wheler J, Troelsen FS, Vágó EK, et al. KRAS mutation and venous thromboembolism risk in colorectal cancer: a Danish population-based cohort study. J Thromb Haemost. 2026. PMID: 42829084. doi:10.1016/j.jtha.2026.09.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。